Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 801–900 of 1,001
Adenosine Potentiates Human Lung Mast Cell Tissue Plasminogen Activator Activity
Sereda, M. J., Bradding, P., & Vial, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001563 · Cited by 16
“receptor subtypes seem to contribute to tPA transcript upregulation (35), and this possibility was supported by our signaling studies.”
MethodResultRegulation of Adenosine Deaminase on Induced Mouse Experimental Autoimmune Uveitis
Liang, D., Zuo, A., Zhao, R., Shao, H., Kaplan, H. J., & Sun, D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502294 · Cited by 16
“The discovery of the potent effects of adenosine on inflammation and immune responses led to attempts at treatment of immune dysfunction by targeting adenosine receptor (AR) signaling (2, 3, 5, 6).”
Background5′‐N‐ethylcarboxamidoadenosine is not a paralog‐specific Hsp90 inhibitor
Liu, S., & Street, T. O. (2016) · Protein Science · doi:10.1002/pro.3049 · Cited by 15
“Adenosine receptors are a family of G-coupled proteins that, upon stimulation from adenosine, activates adenylyl cyclase resulting in a cascade of biological outcomes.(24) Our results suggest that cell biological experiments utilizing NECA may have confounding effects from cytosolic Hsp90 inhibition.”
BackgroundHe, S.-B., Hu, B., Kuang, Z., Wang, D., & De, K. (2016) · Scientific Reports · doi:10.1038/srep36595 · Cited by 16
Tritium-labeled agonists as tools for studying adenosine A2B receptors
Hinz, S., Alnouri, M. W., Pleiß, U., & Müller, C. E. (2018) · Purinergic Signalling · doi:10.1007/s11302-018-9608-5 · Cited by 16
“cluding anti-inflammatory and immune-suppressive activity [7].”
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview
Ben, D. D., Lambertucci, C., Buccioni, M., Navia, A. M., Marucci, G., Spinaci, A., & Volpini, R. (2019) · Pharmaceuticals · doi:10.3390/ph12040150 · Cited by 17
“The stimulation of the various AR subtypes has effects on Central Nervous System (CNS) and peripheral tissues [5,6], modulating release of neurotransmitters, synaptic transmission [7], heart rate and atrial contractility, vascular smooth muscle tone [8], gastrointestinal functions [9,10], as well as renal [11], platel…”
BackgroundInhibition of Adenosine Pathway Alters Atrial Electrophysiology and Prevents Atrial Fibrillation
Soattin, L., Lubberding, A. F., Bentzen, B. H., Christ, T., & Jespersen, T. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00493 · Cited by 17
Deletion of TRPV4 enhances in vitro wound healing of murine esophageal keratinocytes
Boudaka, A., Saito, C. T., & Tominaga, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-68269-8 · Cited by 17
Comeo, E., Trinh, P. N. H., Nguyen, A. T. N., Nowell, C. J., Kindon, N. D., Soave, M., Stoddart, L. A., White, J. M., Hill, S. J., Kellam, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02067 · Cited by 19
Caffeine restores regional brain activation in acute hypoglycaemia in healthy volunteers
Rosenthal, M. J., Smith, D. M., Yágüez, L., Giampietro, V., Kerr, D. E., Bullmore, E. T., Brammer, M. J., Williams, S., & Amiel, S. A. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02131.x · Cited by 17
Lee, H. W., Kim, H. O., Choi, W. J., Choi, S., Lee, J. H., Park, S.-G., Yoo, L. S., Jacobson, K. A., & Jeong, L. S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.018 · Cited by 16
Self-citationCosimelli, B., Taliani, S., Greco, G., Novellino, E., Sala, A., Severi, E., Settimo, F. D., Motta, C. L., Pugliesi, I., Antonioli, L., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201100284 · Cited by 16
Drug-Eluting Stent for Delivery of Signal Pathway-Specific 1,3-Dipropyl-8-cyclopentyl Xanthine
Kang, E., Vedantham, K., Long, X., Dadara, M., Kwon, I.-K., Sturek, M. S., & Park, K. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002623 · Cited by 16
Mor, M., Shaleṿ, A., Dror, S., Pikovsky, O., Beharier, O., Moran, A., Katz, A., & Etzion, Y. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200873 · Cited by 16
“Adenosine, an endogenous nucleoside that activates several cell-surface receptor subtypes (Jacobson and Gao, 2006), is a potent inhibitor of A-V–nodal conduction.”
BackgroundSquarcialupi, L., Betti, M., Catarzi, D., Varano, F., Falsini, M., Ravani, A., Pasquini, S., Vincenzi, F., Salmaso, V., Sturlese, M., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1247060 · Cited by 16
“Among all the available crystallographic structures of hA2A AR cocrystallized with a ligand in the orthosteric binding site, we opted for a complex with the antagonist ZM-241385 because of the structural similarity of its ([1,2,4]triazolo[1,5,a][1,3,5]triazin-5,7-yl)diamine scaffold with the (pyrazolo[4,3-d]pyrimidin-…”
MethodAdenosine receptor activation in the Th17 autoimmune responses of experimental autoimmune uveitis
Li, X., Liang, D., Shao, H., Born, W. K., Kaplan, H. J., & Sun, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.09.004 · Cited by 19
Mallo‐Abreu, A., Majellaro, M., Jespers, W., Azuaje, J., Caamaño, O., Xerardo Garcia-mera, B., Brea, J. M., Loza, M. I., Gutiérrez‐de‐Terán, H., & Sotelo, E. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01340 · Cited by 16
Saku, O., Saki, M., Kurokawa, M., Ikeda, K., Uchida, S., Takizawa, T., & Uesaka, N. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.058 · Cited by 18
Zhang, L., Paine, C., & Dip, R. (2010) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-010-0104-0 · Cited by 17
“A2AAR inactivation amplifies NECA-mediated induction of NR4A2 and NR4A3 Human mast cells express A2A, A2B, and A3ARs (Feoktistov and Biaggioni 1998; Feoktistov et al. 2003).”
BackgroundInfluentialNieto, M. I., Balo, C., Brea, J. M., Caamaño, O., Cadavid, M. I., Fernández, F., Xerardo Garcia-mera, B., López, C., & Rodríguez-Borges, J. E. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.03.029 · Cited by 16
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands
Ben, D. D., Buccioni, M., Lambertucci, C., Thomas, A., Klotz, K., Federico, S., Cacciari, B., Spalluto, G., & Volpini, R. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.006 · Cited by 16
Library Fingerprints: A Novel Approach to the Screening of Virtual Libraries
Klon, A. E., & Diller, D. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci7000204 · Cited by 16
Opposite effects of uracil and adenine nucleotides on the survival of murine cardiomyocytes
Mazzola, A., Amoruso, E., Beltrami, E., Lecca, D., Ferrario, S., Cosentino, S., Tremoli, E., Ceruti, S., & Abbracchio, M. P. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00133.x · Cited by 16
“Upon addition to cells, ATP is quickly degraded to adenosine, which can then activate the P1 receptors (subdivided into the A1, A2A, A2B and A3 subtypes [28]).”
BackgroundMethodMansourian, M., Madadkar-Sobhani, A., Mahnam, K., Fassihi, A., & Saghaie, L. (2012) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1427-y · Cited by 14
Organoruthenium Antagonists of Human A3 Adenosine Receptors
Paira, P., Chow, M. J., Venkatesan, G., Kosaraju, V. K., Cheong, S. L., Klotz, K., Ang, W. H., & Pastorin, G. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201203291 · Cited by 15
Townsend, M. H., Freitas, C. M. T., Larsen, D. J., Piccolo, S., Weber, K. S., Robison, R. A., & O'Neill, K. L. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.151931 · Cited by 16
Rapid Covalent Labeling of Membrane Proteins on Living Cells Using a Nanobody–Epitope Tag Pair
Cabalteja, C. C., Sachdev, S., & Cheloha, R. W. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00334 · Cited by 14
Wang, K., Zhang, F., WEN, C., HUANG, Z., ZHANG, Y., HU, Z., HU, F., & Wen, L. (2021) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.025696 · Cited by 15
“Its primary function is to reduce tissue damage and promote repair through diverse receptormediated mechanisms, including increasing oxygen supply ratio to demand, protecting against ischemic injury, antiinflammatory effects and stimulating angiogenesis [100,101].”
BackgroundHaddad, M., Alsalem, M., Aldossary, S. A., Kalbouneh, H., Jaffal, S. M., Alshawabkeh, Q., Hayek, S. A., Abdelhai, O. S., Barakat, N. A., & El‐Salem, K. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01127-3 · Cited by 17
“Adenosine is naturally occurring purinergic nucleoside that regulates multiple physiological functions including cardiovascular system, immune system, sleep and pain (Jacobson and Gao 2006).”
BackgroundInfluentialPaladines, N., Dawson, S., Ryan, W., Serrano-Lopez, R., Messer, R. L. W., Huo, Y., Cutler, C. W., Ramos‐Junior, E. S., & Morandini, A. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148216 · Cited by 20
“This increases the adenosine concentration (16).”
Arroyave-Ospina, J. C., Buist‐Homan, M., Schmidt, M., & Moshage, H. J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114884 · Cited by 16
Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation
Zhu, W., Hong, Y., Tong, Z., He, X., Li, Y., Wang, H., Gao, X., Song, P., Zhang, X., Wu, X., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101477 · Cited by 18
Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases
Duangrat, R., Parichatikanond, W., Chanmahasathien, W., & Mangmool, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115763 · Cited by 17
“This evidence highlighted the complexity of A 3 AR signaling mechanisms and suggested a potential role of inflammation in both I/R injury and IPC [59,72].”
BackgroundLee, J. H., Lee, S., & Choi, S. (2010) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2010.03.008 · Cited by 15
Biosensor measurement of purine release from cerebellar cultures and slices
Wall, M. J., Eason, R., & Dale, N. (2010) · Purinergic Signalling · doi:10.1007/s11302-010-9185-8 · Cited by 15
“The neuromodulator adenosine is involved in many physiological and pathological CNS processes [1–3].”
Pal, Y., Bandyopadhyay, N., Pal, R. S., Ahmed, S., & Bandopadhyay, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190710111658 · Cited by 16
Wang, X., Jespers, W., Prieto‐Díaz, R., Majellaro, M., IJzerman, A. P., van Westen, G. J. P., Sotelo, E., Heitman, L. H., & Gutiérrez‐de‐Terán, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-93419-x · Cited by 15
Mundell, S. J., Matharu, A. L., Nisar, S. P., Palmer, T., Benovic, J., & Kelly, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00598.x · Cited by 15
Jayasekara, P. S., Phan, K., Tosh, D. K., Kumar, T. S., Moss, S. M., Zhang, G., Barchi, J. J., Gao, Z., & Jacobson, K. A. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9338-z · Cited by 15
“There are four known subtypes of adenosine receptors (ARs), which belong to the superfamily of GPCRs, referred to as A1, A2A, A2B, and A3—each of which has a unique pharmacological profile, tissue distribution, and combination of effects [12, 13].”
BackgroundInfluentialSelf-citationZhong, W., & Little, R. D. (2009) · Tetrahedron · doi:10.1016/j.tet.2009.09.021 · Cited by 15
Smith, K. M., Browne, S. E., Jayaraman, S., Bleickardt, C. J., Hodge, L. M., Lis, E. V., Yao, L., Rittle, S. L., Innocent, N., Mullins, D. E., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.052 · Cited by 15
Safety issues of compounds acting on adenosinergic signalling
Schmidt, J., & Ferk, P. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12720 · Cited by 17
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases
Ben, D. D., Antonioli, L., Lambertucci, C., Spinaci, A., Fornai, M., D’Antongiovanni, V., Pellegrini, C., Blandizzi, C., & Volpini, R. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1743673 · Cited by 14
Xu, J., Yang, Y., Yang, Y., & Xiong, C. (2021) · Genes · doi:10.3390/genes12010125 · Cited by 16
“The adenosine A3 receptor (A3R) coupled to Gi proteins is encoded by ADORA3, suggesting that it is a regulator of inflammatory responses [59].”
BackgroundRomagnoli, R., Baraldi, P. G., Lopez-Cara, L. C., Cruz‐López, O., Moorman, A. R., Massink, A., IJzerman, A. P., Vincenzi, F., Borea, P. A., & Varani, K. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.041 · Cited by 15
Gao, Z., Teng, B., Wu, H., Joshi, B. V., Griffiths, G. L., & Jacobson, K. A. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9107-1 · Cited by 15
“A3AR agonists, such as Cl-IB-MECA (2, Chart 1), are currently in clinical trials for various metastatic and inflammatory conditions [2–5].”
MethodSelf-citationSole, F. D., Cerull, R., Babich, V., Casavola, V., Helmle‐Kolb, C., & Burckhardt, G. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21399 · Cited by 15
“Within the proximal tubule A3AR protein 222 D I S O L E E T A L . are expressed in the apical and basolateral membranes, with an enriched expression on the apical surface of proximal tubule cells (Aarab et al., 1993; Jacobson and Gao, 2006).”
BackgroundPalaniappan, K. K., Gao, Z., Ivanov, A. A., Greaves, R., Adachi, H., Besada, P., Kim, H. O., Kim, A. Y., Choe, S. A., Jeong, L. S., et al. (2007) · Biochemistry · doi:10.1021/bi7001828 · Cited by 15
Self-citationEstrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.
Crain, J. M., & Watters, J. J. (2010) · PubMed · doi:10.2174/1877381801002010148 · Cited by 15
“There are four groups of P1 receptors based on ligand affinity, the G protein type to which they couple, and their biological effects: A1, A2a, A2b, and A3 (reviewed in [33-36].”
BackgroundCharacteristic molecular vibrations of adenosine receptor ligands
Chee, H. K., Yang, J.-S., Joung, J., Zhang, B., & Oh, S. J. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.01.024 · Cited by 15
Li, H., Feng, Q., Tsoi, M. F., Fei, Y., & Cheung, B. M. Y. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa065 · Cited by 14
Affinity prediction on A3 adenosine receptor antagonists: The chemometric approach
Luan, F., Melo, A., Borges, F., & Cordeiro, M. N. D. S. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.032 · Cited by 14
The Adenosine Pathway and Human Immunodeficiency Virus-Associated Inflammation
Hixson, E. A., Borker, P. V., Jackson, E. K., & Macatangay, B. J. C. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab396 · Cited by 17
“Extracellular adenosine activates type 1 purinergic (P1) receptors, which consists of subtypes A1, A2A, A2B, and A3, that modulate adenylyl cyclase and the 3’5’-cyclic monophosphate pathway [15].”
BackgroundWelihinda, A. A., Ravikumar, P., Kaur, M., Mechanic, J., Yadav, S., Kang, G. J., & Amento, E. P. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.07.174 · Cited by 14
Mishra, V. S., Patil, S., Reddy, P. C., & Lochab, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953098 · Cited by 14
“It is a guanine nucleotide-binding protein, and a G-protein coupled adenosine receptor and acts through mitogen-activated protein kinase (MAPK) and protein kinase A (PKA), signaling converging at the cyclic adenosine monophosphate (cAMP) response element (CREB) (12).”
BackgroundPotential for modulation of platelet function via adenosine receptors during inflammation
Boncler, M. A., Bartczak, K., & Różalski, M. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16146 · Cited by 18
“The high affinity of NECA to A 2A adenosine receptor, which undoubtedly has an impact on its vasodilatory and anti-aggregatory activities, does not closely correspond with the selectivity of NECA towards adenosine receptors (Bruns et al., 1986; Jacobson & Gao, 2006).”
BackgroundSynthesis of 2′-([1,2,3]Triazol-1-yl)-2′-deoxyadenosines
O’Mahony, G., Svensson, S., Sundgren, A., & Grøtli, M. (2008) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770802086880 · Cited by 14
Ashton, K. J., Peart, J. N., Morrison, R. R., Matherne, G. P., Blackburn, M. R., & Headrick, J. P. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.12.012 · Cited by 14
Grady, E. E., Barron, J. T., & Wagner, R. H. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9373-0 · Cited by 14
Thomas‐Tran, R., Lee, J. S., Chevalier, V., Sadler, S., Selesniemi, K. L., Hatfield, S. M., Sitkovsky, M. V., Ondrechen, M. J., & Jones, G. B. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.043 · Cited by 14
Urmaliya, V., Pouton, C. W., Devine, S. M., Haynes, J. M., Warfe, L., Scammells, P. J., & White, P. J. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181eb8563 · Cited by 14
Novel 8-heterocyclyl xanthine derivatives in drug development – an update
Baraldi, P. G., Fruttarolo, F., Tabrizi, M. A., Romagnoli, R., & Preti, D. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.9.1161 · Cited by 14
Thomas, A., Buccioni, M., Ben, D. D., Lambertucci, C., Marucci, G., Santinelli, C., Spinaci, A., Kachler, S., Klotz, K., & Volpini, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500595 · Cited by 14
Alachouzos, G., Lenselink, E. B., Mulder‐Krieger, T., de Vries, H., IJzerman, A. P., & Louvel, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.081 · Cited by 14
Pharmacology of Adenosine Receptors and Their Signaling Role in Immunity and Inflammation
Lapa, F. D. R., Macedo-Júnior, S. J., Cerutti, M. L., & Santos, A. R. S. (2014) · InTech eBooks · doi:10.5772/57206 · Cited by 22
“The adenosine A1 receptor is coupled to the Gi/0 family of G proteins, lowering the intracellular levels of cAMP [32, 33].”
BackgroundMethodInfluentialRomagnoli, R., Baraldi, P. G., Carriòn, M. D., Lopez-Cara, L. C., Cruz‐López, O., Salvador, M. K., Preti, D., Tabrizi, M. A., Shryock, J. C., Moorman, A. R., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.044 · Cited by 14
The Structure of the Adenosine Receptors
Lane, J. R., Jaakola, V., & IJzerman, A. P. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00001-1 · Cited by 17
García‐Raso, A., Terrón, Á., López-Zafra, A., García‐Viada, A., Barta, A., Frontera, A., Lorenzo, J., Rodríguez-Calado, S., Vázquez-López, E. M., & Fiol, J. J. (2019) · New Journal of Chemistry · doi:10.1039/c9nj02279a · Cited by 14
Thuraiaiyah, J., Al‐Karagholi, M. A., Elbahi, F. A., Zhuang, Z. A., & Ashina, M. (2022) · Pain · doi:10.1097/j.pain.0000000000002804 · Cited by 13
Adenosine A2A receptors and sleep
Korkutata, M., & Lazarus, M. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.04.007 · Cited by 13
Adenosine A2A receptor and glia
Gao, Z. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.08.002 · Cited by 17
Self-citationMetabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma
Tabata, S., Umemura, S., Narita, M., Udagawa, H., Ishikawa, T., Tsuboi, M., Goto, K., Ishii, G., Tsuchihara, K., Ochiai, A., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0386 · Cited by 16
Structure-based discovery of positive allosteric modulators of the A 1 adenosine receptor
Nguyen, A. T. N., Panel, N., Vo, D. D., Thai, B. S., Chia, L. Y., Lu, C. S., Hellyer, S. D., Langiu, M., Jörg, M., Gregory, K. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2421687122 · Cited by 13
New drugs and targets for asthma and COPD
Hansel, T. T., & Barnes, P. J. (2010) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/000320793 · Cited by 13
Cruz‐Monteagudo, M., Cordeiro, M. N. D. S., Teijeira, M., González, M. P., & Borges, F. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.00971.x · Cited by 13
Keene, A. M., Balasubramanian, R., Lloyd, J., Shainberg, A., & Jacobson, K. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.020 · Cited by 13
“The structure activity relationship (SAR) of nucleoside derivatives as agonists at the ARs has been extensively studied [1].”
Self-citationCheong, S. L., Federico, S., Venkatesan, G., Paira, P., Shao, Y. M., Spalluto, G., Yap, C. W., & Pastorin, G. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.073 · Cited by 13
Glucose decreases extracellular adenosine levels in isolated mouse and rat pancreatic islets
Yang, G. K., Squires, P. E., Tian, F., Kieffer, T. J., Kwok, Y. N., & Dale, N. (2012) · Islets · doi:10.4161/isl.19037 · Cited by 14
“These adenosine receptors have been found to be ubiquitously distributed throughout the body in a nonuniform manner and numerous physiological functions of adenosine have been characterized.(3) A previous study identified adenosine A1 receptors on β- and a-cells as well as adenosine A2A receptors on a-cells, suggestin…”
BackgroundDobson, G. P., Arsyad, A., & Letson, H. L. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00824 · Cited by 16
Gurjar, V. K., & Pal, D. (2019) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2019v11i1.30429 · Cited by 13
“29 last few years toward the discovery and development of selective A2AAR ligands [101].”
BackgroundPak, E. S., Jeong, L. S., Hou, X., Tripathi, S., Lee, J., & Ha, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115667 · Cited by 13
“Furthermore, this leads to activation of cAMP-dependent protein kinase A (PKA), MAPKs, phospholipase C (PLC), and calcium-dependent protein kinases (PKC) pathways [6,7].”
BackgroundDevelopment of Covalent, Clickable Probes for Adenosine A1 and A3 Receptors
Trinh, P. N. H., Chong, D. J. W., Leach, K., Hill, S. J., Tyndall, J. D. A., May, L. T., Vernall, A. J., & Gregory, K. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02169 · Cited by 13
Molecular Simulations and Drug Discovery of Adenosine Receptors
Wang, J., Bhattarai, A., Do, H. N., Akhter, S., & Miao, Y. (2022) · Molecules · doi:10.3390/molecules27072054 · Cited by 17
Adenosine Receptor Antagonists Effect on Plasma-Enhanced Killing
Bauzá, G., Moitra, R., & Remick, D. G. (2013) · Shock · doi:10.1097/shk.0000000000000055 · Cited by 13
“A1 and A3 are inhibitory G protein coupled and inhibit adenylyl cyclase activity; decrease tumor necrosis factor !, IL-12, and KC production; stop mast cell degranulation; and inhibit tissue factor expression (7).”
BackgroundCheong, S. L., Venkatesan, G., Paira, P., Jothibasu, R., Mandel, A. L., Federico, S., Spalluto, G., & Pastorin, G. (2011) · International Journal of Medicinal Chemistry · doi:10.1155/2011/480652 · Cited by 13
“MAPK: mitogen-activated protein kinase MRS5346: 5-((2-(2-(4-(3-(5-amino-2-(furan-2-yl)-7Hpyrazolo[4,3-e][1, 2, 4]triazolo[1,5-c]pyrimidin-7-yl)propyl)phenoxy)acetamido)ethyl)carbamoyl)-2-(6-amino-3-iminio-4,5-disulfonato-3H-xanthen-9-yl)benzoate NECA: N-ethylcarboxamidoadenosine PET: positron emission tomography SCH 6…”
BackgroundInfluentialMin, H. S., Joo, J., Kim, K., Kim, J. E., Ghee, J. Y., Kim, H., Lee, J. E., Han, J., Jeong, L. S., Cha, D. R., et al. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.9.1403 · Cited by 13
“Concentrations of extracellular adenosine vary widely depending on external factors and the degree of stress, tissue types, and activation levels of the 4 adenosine receptors (4).”
BackgroundLoss of ENT1 increases cell proliferation in the annulus fibrosus of the intervertebral disc
Veras, M. A., Tenn, N. A., Kuljanin, M., Lajoie, G., Hammond, J. R., Dixon, S. J., & Séguin, C. A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28051 · Cited by 13
“Ultimately, the adenosine receptors and their associated G proteins can modulate mitogen‐activated protein kinase (MAPK) signaling cascades, which in turn regulate cell proliferation, growth, and differentiation (Jacobson & Gao, 2006; Schulte & Fredholm, 2003).”
BackgroundGobeaux, F., Bizeau, J., Samson, F., Marichal, L., Grillo, I., Wien, F., Yesylevskyy, S. O., Ramseyer, C., Rouquette, M., Lepêtre‐Mouelhi, S., et al. (2020) · Nanoscale · doi:10.1039/c9nr06485k · Cited by 15
Kim, Y., Klutz, A. M., Hechler, B., Gao, Z., Gachet, C., & Jacobson, K. A. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9113-3 · Cited by 13
“Affinities of submicromolar K i values were obtained from the PAMAM-DITC-APEC conjugates at A 2A ARs; however, the selectivity at A 3 AR slightly increased with regard to the binding profile of small molecule monomers.”
InfluentialSelf-citationMacdougall, P. E., Aitken, H. M., Scammells, P. J., Kavanagh, Y., Kyne, S. H., & Schiesser, C. H. (2012) · Chemical Communications · doi:10.1039/c2cc34984a · Cited by 13
Hofer, M., Pospíšil, M., Znojil, V., Hòlá, J., Štreitová, D., & Vacek, A. (2008) · Experimental Biology and Medicine · doi:10.3181/0802-rm-43 · Cited by 13
Ivanov, A. A., Wang, B., Klutz, A. M., Chen, V. L., Gao, Z., & Jacobson, K. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701442d · Cited by 13
Self-citationLane, J. R., Klaasse, E., Lin, J., van Bruchem, J., Beukers, M. W., & IJzerman, A. P. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.041 · Cited by 13
León, D., Castillo, C. A., Albasanz, J. L., & Martı́n, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.06.050 · Cited by 13
Fernández, F., Caamaño, O., Nieto, M. I., López, C., Xerardo Garcia-mera, B., Stefanachi, A., Nicolotti, O., Loza, M. I., Brea, J. M., Esteve, C., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.03.062 · Cited by 13
Yaziji, V., Coelho, A., Maatougui, A. E., Brea, J. M., Loza, M. I., Xerardo Garcia-mera, B., & Sotelo, E. (2009) · Journal of Combinatorial Chemistry · doi:10.1021/cc900044k · Cited by 13
Adenosine A3 Receptors in Muscle Protection
Liang, B. T., Urso, M. L., Zambraski, E. J., & Jacobson, K. A. (2009) · Springer eBooks · doi:10.1007/978-90-481-3144-0_13 · Cited by 13
“Subtype-selective agonists and antagonists of the adenosine receptors have been developed ( Jacobson and Gao 2006 ).”
BackgroundSelf-citationAntonijevic, M., Dallemagne, P., & Rochais, C. (2024) · Medicinal Research Reviews · doi:10.1002/med.22075 · Cited by 13
Microbial Synthesis of Nucleosides: Advances and Prospects
Dai, J., Geng, M., Du, Y., Iqbal, M. W., Yang, H., Shen, X., Wang, J., Sun, X., & Yuan, Q. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00530 · Cited by 12
Sun, L., Li, D., Zhao, M., He, X., Yu, X., Miao, Y., Wang, H., Ren, J. T., & Zang, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025618 · Cited by 12
“Several lines of evidence suggest that adenosine is cardioprotective in patients with congestive heart failure and ischemic heart disease via attenuation of catecholamine release and metabolic responses to b-adrenergic stimulation, which is mainly mediated by A1AR [17].”
Background
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.